Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 6, 2003, Pages 979-981

  Turner, Dan ^a   Brenner, Bluma ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; VIRUS LOAD; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL PHYSIOLOGY;

EID: 0344825778     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.6.979-981.2003     Document Type: Short Survey

References (35)

1. Ait-Khaled, M., A. Rakik, P Griffin, A. Cutrell, M. A Fischl, N. Clumeck, S. B. Greenberg, R. Rubio, B. S. Peters, F. Pulido, J. Gould, G. Pearce, W. Spreen, M. Tisdale, S. Lafon, et al. 2002. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antiviral Ther. 7:43-51.
2. Ait-Khaled, M., C. Stone, G. Amphlett, B. Clotet, S. Staszewski, C. Katlama, M. Tisdale, et al. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689.
3. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
5. Brenner, B. G., D. Turner, and M. A. Wainberg. 2002. HIV-1 drug resistance: can we overcome? Expert Opin. Biol. Ther. 2:751-761.
6. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
7. Descamps, D., P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, G. Collin, C. Delaugerre, S. Robert-Delmas, B. Bazin, J. P. Aboulker, G. Pialoux, F. Raffi, and F. Brun-Vezinet. 2000. Mechanism of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 283:205-211.
8. Diallo, K., B. Brenner, M. Oliveira, D. Moisi, M. Detorio, M. Gotte, and M. A. Wainberg. 2003. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob. Agents Chemother. 47:2376-2379.
9. Eron, J. J. 1996. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 10(Suppl. 5):S11-S19.
10. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, R. Rubin, et al. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
11. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine J. Virol. 66:7128-7135.
12. Inouye, P., E. Cherry, H. Mayla, S. Zolla-Pazner, and M. A. Wainberg. 1998. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:735-740.
13. Jonckheere, H., M. Witvrouw, E. De Clercq, and J. Anne. 1998. Lamivudine resistance of HIV type 1 does not delay development of resistance to non-nucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. AIDS Res. Hum. Retroviruses 14:249-253.
14. Keulen, W., A. van Wijk, R. Schuurman, B. Berkhout, and C. A. Boucher. 1999. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. AIDS 13:1343-1349.
15. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
16. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
17. Maguire, M., M. Gartland, S. Moore, A. Hill, M. Tisdale, R. Harrigan, and J. P. Kleim. 2000. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 14:1195-1201.
18. Menendez-Arias, L. 2002. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 71:91-147.
19. Molina, J. M., G. Chene, F. Ferchal, V. Journot, I. Pellegrin, M. N. Sombardier, C. Rancinan, L. Cotte, I. Madelaine, T. Debord, and J. M. Decazes. 1999. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J. Infect. Dis. 180:351-358.
20. Naeger, L. K, N. A Margot, and M. D. Miller. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther. 6:115-126.
21. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
22. Pallela, F. J., K. M. Delaney, A. C Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
23. Petrella, M., and M. A. Wainberg. 2002. Might the M184V substitution in HIV-1 RT confer clinical benefit?. AIDS Rev. 4:224-232.
24. Picard, V., E. Angelini, A. Maillard, E. Race, F. Clavel, G. Chene, F. Ferchal, and J. M. Molina. 2001. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184:781-784.
25. Preston, B. D., and J. P. Dougherty. 1996. Mechanisms of retroviral mutation. Trends Microbiol. 4:16-21.
26. Quinones-Mateu, M., J. Weber, H. R. Rangel, and B. Charkaborty. 2001. HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. 3:223-242.
27. Rezende, L. F., W. C. Drosopoulos, and V. R. Prasad. 1998. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res. 26:3066-3072.
28. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1998. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
29. Samri, A., G. Haas, J. Duntze, J. M. Bouley, V. Calvez, C. Katlama, and B. Autran. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:9306-9312.
30. Schmitt, M., E. Harrer, A. Goldwich, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer. 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 4:653-658.
31. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, and C. Christopherson. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
32. Sharma, P. L., and C. S. Crumpacker. 1999. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. 73:8448-8456.
33. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
34. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:2282-2288.
35. Wainberg, M. A., H. Salomon, Z Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicolson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.